Patents by Inventor Ewelina B. Kulikowski

Ewelina B. Kulikowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10772894
    Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: September 15, 2020
    Assignee: Resverlogix Corp.
    Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Henrik C. Hansen
  • Publication number: 20200129512
    Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
    Type: Application
    Filed: June 14, 2019
    Publication date: April 30, 2020
    Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. Mclure, Ewelina B. Kulikowski
  • Publication number: 20190091235
    Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2018
    Publication date: March 28, 2019
    Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R.A. Halliday, Henrik C. Hansen
  • Patent number: 10111885
    Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: October 30, 2018
    Assignee: Resverlogix Corp.
    Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R. A. Halliday, Laura M. Tsujikawa
  • Publication number: 20170333419
    Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
    Type: Application
    Filed: August 4, 2017
    Publication date: November 23, 2017
    Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. Mclure, Ewelina B. Kulikowski
  • Publication number: 20170326143
    Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
    Type: Application
    Filed: August 3, 2017
    Publication date: November 16, 2017
    Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. McLure, Ewelina B. Kulikowski
  • Patent number: 9757368
    Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
    Type: Grant
    Filed: April 21, 2010
    Date of Patent: September 12, 2017
    Assignee: Resverlogix Corp.
    Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. McLure, Ewelina B. Kulikowski
  • Publication number: 20160263126
    Abstract: The invention comprises methods of modulating the complement cascade in a mammal and for treating and/or preventing diseases and disorders associated with the complement pathway by administering a compound of Formula I or Formula II, such as, for example, 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethoxyquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 10, 2016
    Publication date: September 15, 2016
    Inventors: Ewelina B. Kulikowski, Dean E. Gilham, Sylwia Wasiak, Christopher R.A. Halliday
  • Publication number: 20160206617
    Abstract: The invention comprises methods for treating and/or preventing cardiovascular, cholesterol, and lipid related disorders, including atherosclerosis, through co-administration of therapeutically effective amounts of RVX-208 or a pharmaceutically acceptable salt thereof and rosuvastatin or a pharmaceutically acceptable salt thereof. The invention further provides compositions comprising a therapeutically effective amount of RVX-208 or a pharmaceutically acceptable salt thereof and a therapeutically effective amount of rosuvastatin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 21, 2014
    Publication date: July 21, 2016
    Applicant: RESVERLOGIX CORP.
    Inventors: Kenneth Eugene LEBIODA, Jan Ove JOHANSSON, F. Allen GORDON, Fabrizio Simone CHIACCHIA, Christopher Ross Armstrong HALLIDAY, Ewelina B. KULIKOWSKI
  • Publication number: 20120059002
    Abstract: Disclosed are methods of regulating interleukin-6 (IL-6) and/or vascular cell adhesion molecule-1 (VCAM-1) and methods of treating and/or preventing cardiovascular and inflammatory diseases and related disease states, such as, for example, atherosclerosis, asthma, arthritis, cancer, multiple sclerosis, psoriasis, and inflammatory bowel diseases, and autoimmune disease(s) by administering a naturally occurring or synthetic quinazolone derivative. The invention provides novel synthetic quinazolone compounds, as well as pharmaceutical compositions comprising those compounds.
    Type: Application
    Filed: April 21, 2010
    Publication date: March 8, 2012
    Inventors: Henrik C. Hansen, Gregory S. Wagner, Sarah C. Attwell, Kevin G. McLure, Ewelina B. Kulikowski